

# Coming soon HCI-003 PDX

**Catalogue number:** 162071

**Sub-type:**

**Images:**

## Contributor

**Inventor:** Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose

**Institute:** The University of Utah Research Foundation

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** Coming soon HCI-003 PDX

**Alternate name:**

**Class:**

**Conjugate:**

**Description:** Please register your interest through the enquiry button (quote not currently available)  
Human breast cancer-derived xenograft that retains high fidelity to original tumour and provides valuable resources for drug discovery and precision oncology. This panel of Patient Derived Xenografts provide models for some of the deadliest forms of breast cancer including drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and HER2+ tumours. Sample taken in 2009 from breast tumour of Caucasian female, age 52 at time of collection with a primary diagnosis of IDC; 2009. Patient had no history of smoking, had not undergone systemic treatment prior to collection, and had clinical metastasis to lymph node and liver. Patient and PDX characteristics were as follows - ER status: positive, PR status: positive, HER2 status: negative. PDX information: PAM50 subtype is HER2 enriched, is estrogen dependent, PTEN positive by IHC, and shows metastasis to lymph node and lung

**Purpose:**

**Parental cell:**

**Organism:**

**Tissue:**

**Model:**

**Gender:** Female

**Isotype:**

**Reactivity:**

**Selectivity:**

**Host:**

**Immunogen:**

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:**

**Production details:** Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptically collected and reimplanted into new m ice or banked. Estrogen-independent ER+ breast PDX models were generated when ER+ PDX tumours were transplated into ovariectomized mice without E2 supplementation.

**Formulation:** Frozen explant from the xenografted tumour

**Recommended controls:**

**Bacterial resistance:**

**Selectable markers:**

**Additional notes:** Additional Information on PDX establishment:

<https://www.nature.com/articles/s43018-022-00337-6/figures/9>

## Target details

**Target:**

**Target alternate names:**

**Target background:**

**Molecular weight:**

**Ic50:**

## Applications

**Application:**

**Application notes:**

## Handling

**Format:**

**Concentration:**

**Passage number:**

**Growth medium:**

**Temperature:**

**Atmosphere:**

**Volume:**

**Storage medium:**

**Storage buffer:**  
**Storage conditions:**  
**Shipping conditions:**

## Related tools

**Related tools:**

## References

**References:**

CancerTools.org